Latest TNF inhibitor Stories
FIRST OF SEVERAL PHASE 3 TRIALS TO REPORT RESULTS INDIANAPOLIS, Dec.
Sales of Biologics Will Contribute Approximately $2.3 Billion to the UC Market in 2023, According to Findings from Decision Resources Group BURLINGTON, Mass., Nov.
Presentations examine certain demographic and clinical disease characteristics that may be indicative of Cimzia® treatment response and remission for moderate to severe Crohn's disease ATLANTA,
AG014 Safe and Well Tolerated, Successful Localized GI Delivery of Drug With No Systemic Exposure GHENT, Belgium, Oct.
Patient Shares For Newer Alternative MOA Agents Are Also Expected To Grow In The Next Six Months, According To Findings From Decision Resources Group BURLINGTON, Mass., Oct.
-- Polyarticular juvenile idiopathic arthritis (JIA) occurs in approximately 25 percent of all JIA patients NORTH CHICAGO, Ill., Oct.
-- HUMIRA is now indicated to treat pediatric patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators
- Currently no approved treatment options available for patients living with HS, a skin disease which impacts approximately 1 percent of the adult population worldwide1,2 COPENHAGEN, Denmark,
An experimental anti-inflammatory drug can protect vulnerable neurons and reduce motor deficits in a rat model of Parkinson’s disease.
- Dermira obtains exclusive rights to develop Cimzia® in psoriasis in the US, Canada and the European Union BRUSSELS and REDWOOD CITY, Calif., July 3, 2014 /PRNewswire/ -- UCB, a global biopharmaceutical
- totally perplexed and mixed up.